Renchi Yang

Oct 7, 2024 | nature.com | Rongfeng Fu |Jia Chen |Wei Liu |Yunfei Chen |Ying Chi |Xiaolei Pei | +3 more

AbstractThe paucity of essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) in individuals younger than 18 years highlights several unresolved issues in diagnosis, clinical outcomes, and treatment strategies. To address these knowledge gaps, we analyzed a large bidirectional cohort consisting of childhood and adolescent ET (CAA-ET, n = 156) and pre-PMF (CAA-preMF, n = 13), as well as adult ET (n = 349).

Apr 3, 2024 | onlinelibrary.wiley.com | Huyen Tran |Renchi Yang |Haihe Laboratory |Tianjin Institutes

CONFLICT OF INTEREST STATEMENT HT has acted as a consultant to CSL Behring, Roche, Pifzer. RY has received speaker/consultancy fees from Novo Nordisk, Pfizer, Roche, Sanofi, Takeda. KF has acted as a consultant and participated in expert groups for Bayer, Biogen, CSL Behring, NovoNordisk, and Sobi, has received research grants from Bayer, NovoNordisk, Pfizer, and has given  invited educational lectures for Bayer, NovoNordisk, and Pfizer, and has received travel support from Sobi and Bayer.